Another nAChR agonist, ABT-418, which has binding affinity for α4β2, α2β2, and α3β4 (Potter et al., 1999), showed some cognitive improvement in the acquisition and retention of verbal information of patients with early AD (Mean MMSE score of 21.4). This evidence concerns the gene CHRNA4 and Alzheimer disease.